Proinflammatory interleukin-26 (IL-26) is involved in chronic inflammation; however, the role of IL-26 in chronic hepatitis B (CHB) remains unknown.
Introduction
Despite the availability of effective vaccine, chronic hepatitis B virus (HBV) infection remains the leading cause of liver diseases, affecting approximately 240 million people worldwide. [1] Patients with chronic hepatitis B (CHB) are at high risk of developing liver cirrhosis and hepatocellular carcinoma, with 500,000 to 1 million deaths globally each year. [2] During HBVinduced chronic hepatic inflammation, adaptive immune cells, especially T cells, play crucial roles in antiviral defense via releasing cytokines and chemokines. [3, 4] Measuring the cytokine and chemokine profiles can help assess disease status and predict clinical outcomes of patients with HBV infection. [5] Interleukin-26 (IL-26) belongs to the IL-10 family and is mainly produced by activated T helper 17 (TH17) cells, a subset of CD4 + T lymphocytes that typically secrets IL-17. [6] IL-26 induces production of proinflammatory cytokines in some epithelial cell lines and myeloid cells through a receptor complex composed of IL-20R1 and IL-10R2. [7] [8] [9] [10] Overexpression of IL-26 has been detected in chronic inflammatory diseases (rheumatoid arthritis, Crohn disease, and hepatitis C), playing a promotive role in inflammatory processes. [7, 11, 12] Although other members of IL-10 family, like IL-10 and IL-22, have been associated with HBV infection pathogenesis and outcome, [13] little is known about the expression pattern and the role of IL-26 in CHB.
Previous studies have suggested a reciprocal relationship between IL-26 and its cellular source Th17 cells in the pathogenesis of chronic inflammation. For example, upregulated mRNA expression of IL-26 correlates with an increased number of orphan nuclear receptor RORgt + Th17 cells in the inflamed colonic lesions of patients with Crohn disease. [8] IL-26 promotes the generation of RORgt + Th17 cells in addition to inducing the production of proinflammatory cytokines in rheumatoid arthritis. [7] In CHB patients, highly enriched circulating and intrahepatic Th17 cells enhance immune activation and liver damage by secreting IL-17A, IL-17F, and IL-22. [14, 15] However, the relationship between IL-26 and Th17 cells in CHB remains unknown.
Telbivudine (LdT) is an FDA-approved antiviral agent that inhibits HBV replication and induces hepatitis B e antigen (HBeAg) seroconversion in patients with CHB. [16, 17] A recent study showed that the circulating Th17 cell frequency and IL-17 level are significantly increased in HBeAg + CHB patients compared with those in the healthy controls. Lower ratios of regulatory T/Th17 cells and their secreted cytokines TGF-b1/IL-17 predict a higher HBeAg seroconversion rate in response to LdT treatment. [18] In this study, to elucidate the expression pattern and cellular source of IL-26 in CHB, we analyzed the changes in the serum and cellular levels of IL-26 and discussed their relationship to the changes in HBeAg, HBV DNA, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and IL-17 levels, across baseline and LdT treatment. Our findings may provide serum IL-26 as a potential biomarker for the immune status of the host and as an indicator for treatment success.
Methods

Patients
This study recruited 30 CHB patients admitted to the Division of Infectious Diseases at Southwest Hospital, Third Military Medical University (Chongqing, China) and 28 healthy controls during 2014-2016. The inclusion criteria of CHB patients were as follows:
the presence of hepatitis B surface antigen (HBsAg) and HBeAg in blood samples [19] ;
no previous systemic antiviral treatment or other medications. Patients with a history of toxic liver damage were excluded.
The demographic and clinical characteristics were collected and summarized in Table 1 . Patients were orally given 600 mg LdT once daily. Peripheral blood samples were collected at baseline (week 0) and at weeks 12, 24, 36, and 52 post treatment. Responses to LdT were classified into 2 types: complete response (undetectable serum HBeAg and the serum HBV DNA level < 50 IU/ml) and partial response (only the serum HBV DNA level < 50 IU/ml). This study was approved by the ethics committee of Southwest Hospital. All procedures were in compliance with the Good Clinical Practice Guidelines and the 1975 Declaration of Helsinki. All patients provided written informed consent prior to study initiation.
Enzyme-linked immunosorbent assay (ELISA)
The serum levels of IL-26 and IL-17 were determined using ELISA kits (IL-26: R&D Systems, Minneapolis, MN, USA; IL-17: eBioscience, San Diego, CA, USA) according to the manufacturer's instructions. A standard concentration curve of IL-26 or IL-17 was established. Serum samples were diluted 2-fold in sample diluent. The concentration of IL-26 or IL-17 in each sample was calculated by comparing the experimental values with the standard curve.
Serological and biochemical analyses of HBV
The serum levels of HBsAg and HBeAg were measured using an Abbott I 2000 automated chemiluminescence immunoassay analyzer (Abbott, IL, USA) as previously described. [20] The amount of serum HBV DNA was determined using a luciferase quantization detection kit (Roche, USA) and quantified using Kaneko method. [21] The serum levels of ALT and AST were measured using an automatic biochemistry analyzer (Hitach, Japan).
CD4 + T cell isolation and flow cytometry assay
Whole blood samples were collected from each subject at weeks 0 (baseline), 12, 24, 36, and 52 post LdT treatment. Peripheral blood mononuclear cells (PBMCs) were separated from heparinized blood samples using an Optipep Nycoprep Lymphoprep kit (Axis-Shield, Oslo, Norway), followed by CD4 + T cells isolation using a CD4 + T cell isolation kit (Miltenyibiotec, Germany). CD4 + T cells were maintained in RPMI 1640 medium (Hyclone, South Logan, UT, USA) supplemented with 10% foetal bovine serum (GIBCO BRL, Grand Island, NY, USA). After stimulation with 1 mg ml À1 phytohaemagglutinin (PHA; Sigma-Aldrich, St. Louis, MO, USA), 100 U ml À1 IL-2 (eBioscience), and 1 ml ml À1 GolgiStop (BD Biosciences, San Jose, CA, USA) for 6 hours, intracellular staining for cytokines were performed using a Cytofix/Cytoperm kit (eBioscience), FITC-conjugated anti-human CD4 (eBioscience), phycoerythrin-conjugated anti-human IL-26 (R&D), allophycocyanin-conjugated anti-human RORgt (eBioscience), and isotype IgG control. The expression of each cytokine was analysed using a FACSAria cell sorter (BD Biosciences) and FlowJo single cell analysis software (Tree Star, Inc., Ashland, OR, USA).
Quantitative real-time RT-PCR
After stimulation with 1 mg ml À1 PHA, 100 U ml À1 IL-2, and 1 ml ml À1 GolgiStop for 6 h, total RNA was isolated from 10 6 CD4 + T cells using TRIzol reagent (TaKaRa, Dalian, China), followed by cDNA synthesis using a PrimeScript RT reagent kit (Takara, Dalian, Chian) according to the manufacturer's instructions. Real-time PCR primers for human RORgt (5'-TGCTGGTT-AGGATGTGCCG-3' and 5'-GAGTGGGAGAAGTCAAA-GATGGA-3'), IL-26 (5'-ATACGCTTTGTGGAGGACTTT-3' and 5'-TTGGCTTTGGTTTACTGACTG-3'), and GAPDH (5'-CGGAGTCAACGGATTTGGTCGTAT-3' and 5'-AGCCTTCT Table 1 Clinical characteristics of study participants.
Parameters
Healthy controls (n = 28) CHB patients (n = 30) 
Results
Demographic and clinical characteristics of study participants
A total of 30 patients with chronic HBV (21 men and 9 women; 25-53 years old) and 28 healthy controls (16 men and 12 women;
22-49 years old) were recruited at the Department of Infectious Diseases of Southwest Hospital. The demographic and clinical characteristics of participants were summarized in Table 1 . CHB patients exhibited increased serum levels of HBV DNA, ALT, and AST, compared with healthy controls at baseline.
Reduced serum IL-26 level accompanies with decreased HBV infection indicators during LdT treatment in HBV patients
To explore the role of IL-26 in CHB, we monitored the serum levels of IL-26, HBV DNA, ALT, and AST in CHB patients across baseline and LdT treatment. As shown in Figure 1A and 1B, compared with healthy controls, CHB patients had remarkably increased baseline serum levels of both HBV DNA and IL-26 that were significantly and time-dependently reduced in response to LdT treatment. Because HBeAg clearance indicates the therapeutic effect of LdT, [17] we compared the serum IL-26 levels between HBeAg-positive CHB patients at baseline and HBeAg-negative patients at week 24 and 52 post treatment. We found that the serum IL-26 level was dramatically decreased upon HBeAg clearance (Fig. 1C) . Similarly, the serum IL-26 levels in patients with normal ALT or AST levels ( 40 U/L) were significantly lower than those in patients with elevated ALT or AST levels (> 40U/L) ( Fig. 2A and  2B) . The serum IL-26 level exhibited a consistent time-dependent downward trend with ALT and AST in HBV patients during LdT treatment ( Fig. 2C and 2D ). Taken together, these results suggest that the serum IL-26 level may serve as a potential auxiliary indicator for CHB prognosis and LdT treatment success.
The serum IL-26 level positively correlates with the ALT and AST levels in CHB patients at baseline
We further evaluated the correlation of the serum IL-26 level with the ALT, AST, and HBV DNA levels in CHB patients at baseline. As shown in Figure 3A -C, the serum IL-26 level was significantly and positively correlated with the ALT or AST levels, but not with the HBV DNA level, suggesting that the increased serum IL-26 level could indicate liver damage in CHB.
Reduced serum IL-26 coincides with decreased serum IL-17 during LdT treatment in CHB patients
Th17 cells secret both IL-17 and IL-26. [6] Despite a lack of correlation with the serum IL-26 level ( Fig. 4A , P = .969), the serum IL-17 level in CHB patients was significantly higher than those in healthy controls at baseline that was significantly and time-dependently declined during LDT treatment (Fig. 4B) , consistent with that observed in the serum IL-26 level (Fig. 1B) . These data suggest that IL-17-secreting Th17 cells could be a possible source of circulating IL-26 in CHB patient. The serum levels of TNF-a and IL-23 were also detected in the CHB patients at weeks 0 (baseline), 12, 24, 36, and 52 post LdT therapy. The serum level of the 2 Inflammatory factor in CHB patients didn't change like IL-17 that was so obvious when treated ( Fig. S1 , http://links.lww.com/MD/D516).
IL-26 is abundantly expressed in CHB patient-derived CD4 + T cells
To investigate the cellular source of circulating IL-26 in CHB patients, we performed flow cytometric detection of IL-26 protein in CD4and CD4 + lymphocytes sorted from PBMCs of healthy controls and CHB patients. As shown in Figure 5A , the percentage of IL-26-expressing CD4 + cells was significantly increased in CHB patients compared with that in healthy controls. In CHB patients, the percentage of IL-26-expressing CD4 + cells was considerably higher than that of IL-26-expressing CH4cells. Consistent results were observed in cellular IL-26 mRNA expression ( Fig. 5B) . These data suggest that IL-26 might be mainly expressed by CD4 + T cells in CHB patients. In addition, the baseline mRNA levels of both IL-26 and RORgt (a master transcription factor governing Th17 cell differentiation [22] were significantly elevated in CHB patient-derived CD4 + T cells compared with those in healthy control-derived CD4 + T cells. During LdT treatment, the mRNA levels of IL-26 and RORgt showed similar declining trends (Fig. 5C) . A significant and (Fig. 5D ). Flow cytometric analysis showed that IL-26 and RORgt were coexpressed in 3.4% of CD4 + T cells (Fig. 5E) . These results suggest a close relationship between circulating IL-26 and Th17 CD4 + cells.
Discussion
HBV infection can cause chronic inflammation that involves various immunocytes and proinflammatory cytokines. [23] Proinflammatory cytokine IL-26 contributes to chronic inflammation in multiple autoimmune diseases. [7, 11, 12] In this study, we demonstrated that the baseline serum IL-26 level was significantly increased in patients with CHB compared with that in healthy controls and that reduced serum IL-26 level coincided with decreased HBV infection indicator levels during LdT therapy, suggesting that circulating IL-26 could indicate the therapeutic effect of LdT in CHB patients. We also found a positive correlation between baseline IL-26 and RORgt mRNA levels in CHB patient-derived CD4 + T cells and observed similar declining trends in circulating IL-26 and IL-17 levels as well as in cellular mRNA expression of IL-26 and RORgt, suggesting that IL-26, IL-17, and RORgt might have the same cellular source (i.e., Th17 cells) in CHB patients. In this study, the baseline serum IL-26 level was significantly increased in CHB patients compared with that in healthy controls and was gradually decreased during LdT treatment, consistent with that observed in HBV DNA, ALT, and AST, suggesting a role of IL-26 in the inflammatory processes in CHB. Studies have shown that IL-26 plays an antiviral role in primary immune cells, epithelial cells, and keratinocyte cells [9, 24, 25] by producing proinflammatory cytokines through activating IL-20R1/IL-20R2 complex. Although little is known about the role of IL-26 in chronic HBV infection, a recent study have described that IL-26 can stimulate CD16 -CD56 bright natural killer (NK) cells to remove HCV-infected hepatocytes by enhancing the expression of tumor necrosis factor-related apoptosis-inducing ligand on NK cell membranes. [12] In addition, IL-26 induces the expression of type I interferon in plasmacytoid dendritic cells by binding to Toll-like receptor 9, further interfering viral replication and reducing damage to hepatocytes. [26] We therefore speculate that IL-26 might have a similar role in chronic HBV infection.
Our results showed that the serum ALT, AST, and HBV DNA levels were consistently declined during LdT treatment in a timedependent manner, in agreement with previous studies. [14, 15, 18] In addition, the serum IL-26 level was significantly decreased upon HBeAg clearance after LdT treatment. These data suggest that the circulating IL-26 level may serve as an indicator for treatment success in CHB. Furthermore, the baseline serum IL-26 level positively correlated with ALT and AST levels in CHB patients, suggesting that increased serum IL-26 can indicate liver injury in CHB. Despite a lack of correlation between the serum levels of IL-26 and IL-17 in this study, previous investigations have shown that Th17 cell frequency and the IL-17 level positively correlate with the ALT level in CHB (P < .05), [18] To further investigate the cellular source of serum IL-26 in CHB, we tested the protein and mRNA expression of IL-26 in CD4and CD4 + lymphocytes derived from healthy controls and CHB patients. Our results suggest that serum IL-26 might be mainly released from CD4 + T cells, evidenced by the significantly increased percentage of IL-26-expressing CD4 + cells compared with that of IL-26-expressing CD4cells isolated from the PBMC of CHB patients. Furthermore, the mRNA levels of IL-26 and RORgt were positively correlated and displayed the same declining trend across the baseline and LdT treatment. Although RORgt expression is not only confined in Th17 cells, [27] RORgt, as a transcription factor, can control the expression of key genes in Th17 cells. Knockdown of RORgt reduces the expression of a number of genes, including IL-17A, IL-17F, IL-22, and IL-26, during Th17 differentiation, [28] consistent with the same expression patterns of IL-17, IL-26, and RORgt observed in CHB patients across the baseline and LdT treatment. We therefore speculate that the Th17 subset of CD4 + T cells might be one of the cellular sources of circulating IL-26 in CHB patients.
Previous research shows that the viral infectivity modulation capability of IL-26 is dependent on the expression of IL-26 receptor (IL-26R). It is known that the IL-26R consists of the IL-20R1 and IL-10R2 receptor chains that are expressed differently in different tissues. The heterodimeric structure IL-10R2/IL-20R1 has been initially described as an IL-26 receptor on epithelial cells, which signals via STAT1 and STAT3. However, converging evidences support the existence of a distinct IL-26 receptor on immune cells unlike that on epithelial cells. [28] We detected respectively the mRNA and protein levels of IL-10R2 and IL-20R1 in liver specimens of normal people and hepatitis B patients, and found that there was no statistical difference between them. IL-10R2 and IL-20R1 can be expressed in liver cells of CHB, and are not affected by HBV infection (Fig. S2 , http://links.lww.com/MD/D517). Unfortunately, we did not do dimeric IL-26 receptor research in liver tissue. The nature of the IL-26 receptor expressed by human immune cells is undergoing further research.
In summary, compared with healthy controls, CHB patients have significantly increased serum IL-26 levels at baseline that is time-dependently decreased during LdT treatment, consistent with HBV infection indicators like the serum HBV DNA, ALT, and AST levels. In addition, the expression patterns of serum and cellular IL-26 are similar to those of IL-17 and RORgt, respectively, suggesting that IL-17-and RORgt-expressing Th17 cells are possible cellular source of serum IL-26 elevation in CHB patients. Our results suggest IL-26 as a novel potential indicator for inflammation in chronic HBV infection and provide some new information about the mechanism underlying the serum IL-26 elevation in CHB patients.
